Showing results (1-10 of 77) with videos related to
Sort By:
Pageof 8
Current Oncology (Toronto, Ont.)|April 25, 2025
Cost-Effectiveness Analysis of Contemporary Advanced Prostate Cancer Treatment SequencesValentyn Litvin, Armen G Aprikian, Alice DragomirValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
Comparison of persistence rates with angiotensin-converting enzyme inhibitors used in secondary and primary prevention of cardiovascular diseaseAmédé Gogovor, Alice Dragomir, Michelle Savoie, et al.Neurourology and Urodynamics|April 11, 2018
A cost-utility analysis of artificial urinary sphincter versus AdVance male sling in post prostatectomy stress urinary incontinence: A publicly funded health care perspectiveSamer Shamout, Sara Nazha, Alice Dragomir, et al.CMAJ Open|August 1, 2014
Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparisonAlice Dragomir, Fabio L Cury, Armen G AprikianJournal of Oncology Practice|May 21, 2019
Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate CancerJason Hu, Armen G Aprikian, Marie Vanhuyse, et al.Cancer Medicine|February 14, 2024
Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based studyPatricia Grisel Quintana Bárcena, Armen Garo Aprikian, Alice DragomirJournal of the National Comprehensive Cancer Network : JNCCN|October 6, 2020
Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate CancerJason Hu, Armen G Aprikian, Marie Vanhuyse, et al.Clinical Genitourinary Cancer|October 28, 2021
Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World DataJason Hu, Armen G Aprikian, Marie Vanhuyse, et al.Cancers|January 11, 2025
Cost-Effectiveness of PARP Inhibitors for Patients with BRCA1/2-Positive Metastatic Castration-Resistant Prostate Cancer-The Canadian PerspectiveIvan Yanev, Armen G Aprikian, Brendan L Raizenne, et al.Plos One|December 5, 2014
Clinical management and burden of prostate cancer: a Markov Monte Carlo modelChiranjeev Sanyal, Armen Aprikian, Fabio Cury, et al.Pageof 8